Disease Landscape and Forecast 인사이트

What Clinical Attributes Will Be Most Persuasive for Psychiatrists and Payers Regarding the First Novel Drugs in this Highly Underserved Arena? Decision Resources Group forecasts the number of…

Amid Substantial Unmet Need, What Magnitude of Efficacy and Safety Do Neurologists and Payers Expect of a First-To-Market Therapy for Primary-Progressive Multiple Sclerosis? Despite contributing…

What Clinical Attributes Will Be Most Persuasive for Psychiatrists and Payers Regarding the First Novel Drugs in this Highly Underserved Arena? Decision Resources Group forecasts the number of…

LaunchTrends: Tafinlar and Mekinist is a series of three post-launch syndicated reports designed to track physician perception and uptake of newly launched Tafinlar (GlaxoSmithKline’s dabrafenib…

TreatmentTrends: Multiple Sclerosis (US) is an annual syndicated report that provides a comprehensive view of the current and anticipated management of multiple sclerosis (MS) based on primary…

Treatment for breast cancer (CaB) in the United States has matured as oncologists have formalized protocols around specific patient populations, namely HER2+, HR+/HER2-, and HR-/HER2- (also known…

How Will the Complex Interplay Between Benefit, Risk, and Cost Impact Prescriber Preferences, and Payer Acceptance of, Future Disease-Modifying Therapies? The market for disease-modifying…

How Will the Complex Interplay Between Benefit, Risk, and Cost Impact Prescriber Preferences, and Payer Acceptance of, Future Disease-Modifying Therapies? The market for disease-modifying…

How Will Physicians and Payers Value Advances in Drug Delivery? Opioid addiction is a debilitating, chronic relapsing disorder affecting nearly 5 million people in the seven major markets under…

How Will Physicians and Payers Value Advances in Drug Delivery? Opioid addiction is a debilitating, chronic relapsing disorder affecting nearly 5 million people in the seven major markets under…

Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the…

LaunchTrends®: Perjeta and Kadcyla is a series of four post-launch syndicated reports designed to track physician perception and uptake of newly launched Perjeta (Roche/Genentech’s pertuzumab)…